Biocon Ltd

Past performance
Performance overview
Biocon Ltd
About Biocon Ltd Biocon Limited is India's largest biopharmaceutical company, focusing on biotechnology products and research services. Established in 1978, it has evolved from enzyme exports to become a major player in the biopharmaceutical and biosimilars arena. Biocon is known for pioneering initiatives in human healthcare, including the production of statins and biopharmaceuticals, and has received several FDA approvals for products like lovastatin and biosimilar insulin. Over the years, Biocon has expanded its operations globally, establishing significant partnerships with companies like Mylan and Sandoz for biosimilars development and commercialization. Biocon's portfolio includes a range of therapeutic products, such as insulin glargine, immunosuppressants, and oncology drugs. It has also made strategic moves to enhance its manufacturing capabilities, including the setup of a large-scale insulin production facility in Malaysia and the recent commissioning of a fermentation-based API facility in India. Biocon continues to strengthen its global footprint through partnerships and regulatory approvals, expanding its market presence in regions like the EU, U.S., and Asia. The company remains committed to innovation and research, advancing its pipeline with new biosimilars and formulations.
Website biocon.com
Founded 1978
Headquarters Bangalore